Symbollon Pharmaceuticals Files Patent Application Covering Use Of Its Technology In Upper Respiratory Tract To Safely Kill Pathogens Without Drug Resistance

Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) today announced that the company has filed a patent application covering use of its free molecular iodine technology to eradicate pathogens and inhibit superantigens from activating immune cells in the upper respiratory tract. This patent application will significantly extend Symbollon's proprietary coverage of administering its active agent, molecular iodine, to the upper respiratory tract.

Back to news